JP5653219B2 - 水素結合サロゲートをベースとする人工ヘリックスによるウイルス宿主膜融合の制御 - Google Patents

水素結合サロゲートをベースとする人工ヘリックスによるウイルス宿主膜融合の制御 Download PDF

Info

Publication number
JP5653219B2
JP5653219B2 JP2010540953A JP2010540953A JP5653219B2 JP 5653219 B2 JP5653219 B2 JP 5653219B2 JP 2010540953 A JP2010540953 A JP 2010540953A JP 2010540953 A JP2010540953 A JP 2010540953A JP 5653219 B2 JP5653219 B2 JP 5653219B2
Authority
JP
Japan
Prior art keywords
peptide
amino acid
helix
carbon
bond
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010540953A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011507972A5 (enExample
JP2011507972A (ja
Inventor
ワン，デユン
アローラ，パラムジット
Original Assignee
ニューヨーク ユニバーシティ
ニューヨーク ユニバーシティ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ニューヨーク ユニバーシティ, ニューヨーク ユニバーシティ filed Critical ニューヨーク ユニバーシティ
Publication of JP2011507972A publication Critical patent/JP2011507972A/ja
Publication of JP2011507972A5 publication Critical patent/JP2011507972A5/ja
Application granted granted Critical
Publication of JP5653219B2 publication Critical patent/JP5653219B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2010540953A 2007-12-31 2008-12-31 水素結合サロゲートをベースとする人工ヘリックスによるウイルス宿主膜融合の制御 Expired - Fee Related JP5653219B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1811807P 2007-12-31 2007-12-31
US61/018,118 2007-12-31
PCT/US2008/088667 WO2009110952A2 (en) 2007-12-31 2008-12-31 Control of viral-host membrane fusion with hydrogen bond surrogate-based artificial helices

Publications (3)

Publication Number Publication Date
JP2011507972A JP2011507972A (ja) 2011-03-10
JP2011507972A5 JP2011507972A5 (enExample) 2012-02-23
JP5653219B2 true JP5653219B2 (ja) 2015-01-14

Family

ID=41056505

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010540953A Expired - Fee Related JP5653219B2 (ja) 2007-12-31 2008-12-31 水素結合サロゲートをベースとする人工ヘリックスによるウイルス宿主膜融合の制御

Country Status (5)

Country Link
US (1) US8871899B2 (enExample)
EP (1) EP2247298B1 (enExample)
JP (1) JP5653219B2 (enExample)
CA (1) CA2710964A1 (enExample)
WO (1) WO2009110952A2 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2489360A1 (en) * 2006-11-15 2012-08-22 Dana-Farber Cancer Institute, Inc. Stabilized MAML peptides and uses thereof
BRPI0720306A2 (pt) 2006-12-14 2014-02-04 Aileron Therapeutics Inc Sistemas de macrociclização da bis-sufidrila
CA2678941C (en) 2007-02-23 2018-11-27 Aileron Therapeutics, Inc. Triazole macrocycle systems
JP5631201B2 (ja) 2007-03-28 2014-11-26 プレジデント アンド フェローズ オブ ハーバード カレッジ ステッチングされたポリペプチド
US8613956B2 (en) * 2008-06-23 2013-12-24 International Flora Technologies, Ltd. Cosmetic particles that transform from hard to soft particles comprising hydrogenated long-chain triglyceride oils
CA2737922A1 (en) 2008-09-22 2010-03-25 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
AU2009316288B2 (en) 2008-11-24 2016-05-19 Aileron Therapeutics, Inc. Peptidomimetic macrocycles with improved properties
BRPI1006139A2 (pt) 2009-01-14 2017-05-30 Aileron Therapeutics Inc macrociclos peptidomiméticos
WO2011038049A1 (en) 2009-09-22 2011-03-31 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
KR20180058866A (ko) 2010-08-13 2018-06-01 에일러론 테라퓨틱스 인코포레이티드 펩티도미메틱 거대고리
WO2013059530A2 (en) * 2011-10-18 2013-04-25 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
BR112014009418A2 (pt) 2011-10-18 2017-04-18 Aileron Therapeutics Inc macrociclos peptidomiméticos
WO2013123267A1 (en) 2012-02-15 2013-08-22 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
CN112500466B (zh) 2012-02-15 2022-05-03 艾瑞朗医疗公司 拟肽大环化合物
MX2015005244A (es) 2012-11-01 2015-07-14 Aileron Therapeutics Inc Aminoacidos disustituidos y metodos de preparacion y el uso de los mismos.
US20140205681A1 (en) 2013-01-19 2014-07-24 New York University HYDROGEN-BOND SURROGATE PEPTIDES AND PEPTIDOMIMETICS FOR p53 REACTIVATION
EP3041492A4 (en) * 2013-09-03 2017-08-02 New York University INHIBITING INTERACTION BETWEEN HIF-1alfa AND P300/CBP WITH HYDROGEN BOND SURROGATE-BASED HELICES
AU2015320545C1 (en) 2014-09-24 2020-05-14 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and formulations thereof
AU2015320549A1 (en) 2014-09-24 2017-04-13 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
SG11201707750YA (en) 2015-03-20 2017-10-30 Aileron Therapeutics Inc Peptidomimetic macrocycles and uses thereof
WO2017004548A1 (en) 2015-07-01 2017-01-05 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
CN108368161A (zh) 2015-09-10 2018-08-03 艾瑞朗医疗公司 作为mcl-1调节剂的拟肽大环化合物
CN108822190B (zh) * 2018-05-23 2021-11-09 中国人民解放军军事科学院军事医学研究院 多肽及其药物组合物和用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5446128A (en) * 1993-06-18 1995-08-29 The Board Of Trustees Of The University Of Illinois Alpha-helix mimetics and methods relating thereto
US5840833A (en) * 1995-10-27 1998-11-24 Molecumetics, Ltd Alpha-helix mimetics and methods relating thereto
US6841657B2 (en) * 1997-04-17 2005-01-11 Whitehead Institute For Biomedical Research Inhibitors of HIV membrane fusion
US6150088A (en) * 1997-04-17 2000-11-21 Whitehead Institute For Biomedical Research Core structure of gp41 from the HIV envelope glycoprotein
US6818740B1 (en) * 1997-04-17 2004-11-16 Whitehead Institute For Biomedical Research Inhibitors of HIV membrane fusion
US6596497B1 (en) * 1999-03-17 2003-07-22 New York Blood Center, Inc. Screening of antiviral compounds targeted to the HIV-1 gp41 core structure
US7192713B1 (en) * 1999-05-18 2007-03-20 President And Fellows Of Harvard College Stabilized compounds having secondary structure motifs
US20030082525A1 (en) * 1999-12-16 2003-05-01 Whitehead Institute For Biomedical Research Five-Helix protein
US7045552B2 (en) * 2002-09-27 2006-05-16 Trimeris, Inc. Pharmaceutical composition for improved administration of HIV gp41-derived peptides, and its use in therapy
ES2437567T3 (es) * 2003-11-05 2014-01-13 Dana-Farber Cancer Institute, Inc. Péptidos alfa helicoidales estabilizados y utilizaciones de los mismos
PL1745078T3 (pl) * 2004-04-23 2009-12-31 Conjuchem Biotechnologies Inc Sposób oczyszczania koniugatów albumin
US7202332B2 (en) * 2004-05-27 2007-04-10 New York University Methods for preparing internally constrained peptides and peptidomimetics
EP1755667B1 (en) * 2004-06-01 2013-07-17 Merck Sharp & Dohme Corp. Stable peptide mimetic of hiv gp41 fusion intermediate
BRPI0720306A2 (pt) * 2006-12-14 2014-02-04 Aileron Therapeutics Inc Sistemas de macrociclização da bis-sufidrila
US7981998B2 (en) * 2006-12-14 2011-07-19 Aileron Therapeutics, Inc. Bis-sulfhydryl macrocyclization systems
CA2678941C (en) * 2007-02-23 2018-11-27 Aileron Therapeutics, Inc. Triazole macrocycle systems
JP5631201B2 (ja) * 2007-03-28 2014-11-26 プレジデント アンド フェローズ オブ ハーバード カレッジ ステッチングされたポリペプチド
WO2009108261A2 (en) 2008-01-23 2009-09-03 Dana Farber Cancer Institute Compositions and methods for the treatment of viral infections
CA2737922A1 (en) * 2008-09-22 2010-03-25 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
AU2009316288B2 (en) * 2008-11-24 2016-05-19 Aileron Therapeutics, Inc. Peptidomimetic macrocycles with improved properties
CA2777700A1 (en) * 2009-10-14 2011-04-21 Aileron Therapeutics, Inc. Improved peptidomimetic macrocycles

Also Published As

Publication number Publication date
US8871899B2 (en) 2014-10-28
EP2247298A2 (en) 2010-11-10
EP2247298B1 (en) 2016-08-31
EP2247298A4 (en) 2012-06-06
WO2009110952A3 (en) 2010-03-04
CA2710964A1 (en) 2009-09-11
WO2009110952A2 (en) 2009-09-11
US20110046043A1 (en) 2011-02-24
JP2011507972A (ja) 2011-03-10

Similar Documents

Publication Publication Date Title
JP5653219B2 (ja) 水素結合サロゲートをベースとする人工ヘリックスによるウイルス宿主膜融合の制御
Wang et al. Discovery of hydrocarbon-stapled short α-helical peptides as promising Middle East respiratory syndrome coronavirus (MERS-CoV) fusion inhibitors
US8093353B2 (en) Agents for treatment of HCV and methods of use
JP4925540B2 (ja) ５−ヘリックスタンパク質
JP4682251B2 (ja) 改善された生物学的特性を有するｈｉｖ融合阻害剤ペプチド
US20080269462A1 (en) Peptide inhibitors of HIV entry
US11680086B2 (en) Lipopeptide for potently inhibiting HIV, derivative thereof, pharmaceutical composition thereof and use thereof
JP2008505059A (ja) 特異的ウイルス標的用化合物
CA2423004C (en) Peptide inhibitors of hiv entry
US20030219451A1 (en) Stable helical C peptides and uses therefor
WO2018141089A1 (zh) 广谱抑制hiv的脂肽、其衍生物、其药物组合物及其用途
Steger III Kinetic restriction of HIV-1 entry inhibition
Suntoke HIV entry: a biophysical and mutational analysis of gp41-mediated membrane fusion and its inhibition

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111228

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20111228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131025

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140116

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140123

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140220

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140227

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140324

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140331

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140425

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20141022

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20141118

R150 Certificate of patent or registration of utility model

Ref document number: 5653219

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees